Otros idiomas Alnylam Pharmaceuticals, Inc.

Acciones

ALNY

US02043Q1076

Farmacéuticos

Tiempo real estimado Cboe BZX Otros sitios de cotización 17:59:19 14/07/2026			Variación 5 días	Varia. 1 de enero.
281,01 ^USD	-2,45 %		-12,73 %	-29,42 %

16:51	Los resultados del segundo trimestre de Alnylam Pharmaceuticals marcarán el rumbo de los ingresos para 2026, según BofA Securities	MT
15:03	ALNYLAM PHARMACEUTICALS, INC. : recomendación de compra de BofA Securities	ZM

Otros idiomas

16:51	Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
09/07	Aktien New York: Nasdaq profitiert von Chip-Aktien - Dow unbewegt
09/07	Aktien New York Ausblick: Dow stabil erwartet trotz neuer Angriffe in Nahost
09/07	AstraZeneca's Wainua fails key heart disease trial, shares tumble
25/06	Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform
25/06	Alnylam Pharmaceuticals Expands Partnership With Komodo to Extend AI Platform Across Enterprise Functions
25/06	US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
22/06	Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
12/06	Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
10/06	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets
04/06	Bourse : Commerzbank se rebiffe, Broadcom s'étale, Rémy Cointreau rassure
04/06	L'exceptionnel ne suffit pas toujours
04/06	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
03/06	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics
03/06	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
03/06	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
27/05	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026
19/05	Alnylam Issues 2025 Corporate Responsibility Report
19/05	Alnylam Pharmaceuticals : 2025 REPORT
13/05	De nouvelles analyses de données présentées lors du congrès Heart Failure 2026 démontrent les bénéfices cliniques solides et constants du vutrisiran en tant qu’option thérapeutique de première intention chez toutes les populations
13/05	Heart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast
12/05	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients
12/05	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
07/05	Alnylam to Webcast Presentations at Upcoming Investor Conferences
05/05	Alnylam présentera de nouvelles analyses lors du congrès Heart Failure 2026, soulignant le profil clinique constant du vutrisiran dans l’ATTR-CM